Cue Biopharma, Inc. ( CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Lucinda Warren - Interim CEO, Interim President,Principal ...
Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to ...
Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...
Moby summary of Bicara Therapeutics Inc. Common Stock's Q4 2025 earnings call ...
Bicara Therapeutics (NASDAQ:BCAX) used its inaugural quarterly earnings call to highlight recent regulatory momentum, updated ...
Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the ...
The National Comprehensive Cancer Network (R) (NCCN (R) )--an alliance of leading cancer centers--announces the 2026 recipients for the annual NCCN Foundation (R) Young Investigator Awards. The awards ...
Tooth root development relies on precise coordination of cellular signals, yet the underlying mechanisms remain unclear. Researchers have uncovered how two proteins, Gli2 and Gli3, work together to ...
Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the potential intended mechanistic effect of CUE-501 for T cell- ...
MRNA COVID-19 vaccination and cancer risk are examined in a case report and review that explores a reported temporal ...
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains ...
Tooth root formation is a critical process that anchors teeth within the jaw and ensures proper oral function. This complex developmental event ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results